FOXP3 and colitis: Previously, we and others have demonstrated that IL-33 ameliorates experimental colitis through promoting Th2/Foxp3 + regulatory T Cell responses in the experimental colitis in mice [7–10], and IL-33 expression actually increased in the inflamed mucosa of IBD patients, in particular in UC patients.